| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Center for Neuro-Oncology (L.D., D.C.G., S.SK, J.D., R.K., J.Z., L.O., P.Y.W.), Dana Farber/Brigham and Women's Cancer Center and Division of Cancer Neurology (S.K., J.D., P.Y.W.), Department of Neurology, Brigham and Women's Hospital, Boston, MA.
Address correspondence and reprint requests to Dr. Patrick Y. Wen, Center for Neuro-Oncology, Dana Farber/Brigham and Women's Cancer Center, SW430D, 44 Binney Street, Boston, MA 02115; e-mail: pwen{at}partners.org
Malignant gliomas are frequently characterized by amplification of the epidermal growth factor receptor (EGFR) and loss of PTEN tumor suppressor gene. Twenty-eight heavily pretreated patients with recurrent malignant gliomas were administered EGFR inhibitors (gefitinib or erlotinib) in combination with the mTOR (mammalian target of rapamycin) inhibitor sirolimus. The regimens were reasonably well tolerated. Nineteen percent of patients experienced a partial response and 50% had stable disease. Six-month progression-free survival for glioblastoma patients was 25%.
Supported by the Amos Wasgatt, Will Kraft, and Samuel Longo Brain Tumor Research Funds.
Disclosure: The authors report no conflicts of interest.
Received January 12, 2006. Accepted in final form March 13, 2006.
This article has been cited by other articles:
|
|
 |
|
  L. H. Wei, H. Su, I. J. Hildebrandt, M. E. Phelps, J. Czernin, and W. A. Weber Changes in Tumor Metabolism as Readout for Mammalian Target of Rapamycin Kinase Inhibition by Rapamycin in Glioblastoma Clin. Cancer Res., June 1, 2008; 14(11): 3416 - 3426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Ziegler, A. L. Kung, and M. W. Kieran Anti-Apoptosis Mechanisms in Malignant Gliomas J. Clin. Oncol., January 20, 2008; 26(3): 493 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. G. Puffenberger, K. A. Strauss, K. E. Ramsey, D. W. Craig, D. A. Stephan, D. L. Robinson, C. L. Hendrickson, S. Gottlieb, D. A. Ramsay, V. M. Siu, et al. Polyhydramnios, megalencephaly and symptomatic epilepsy caused by a homozygous 7-kilobase deletion in LYK5 Brain, July 1, 2007; 130(7): 1929 - 1941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dantal and E. Pohanka Malignancies in renal transplantation: an unmet medical need Nephrol. Dial. Transplant., May 1, 2007; 22(suppl_1): i4 - i10. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gutierrez-Dalmau and J. M. Campistol The role of proliferation signal inhibitors in post-transplant malignancies Nephrol. Dial. Transplant., May 1, 2007; 22(suppl_1): i11 - i16. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. V. Bradley, E. C. Holland, G. Y. Liu, D. Thomas, T. S. Hyun, and T. S. Ross Huntingtin Interacting Protein 1 Is a Novel Brain Tumor Marker that Associates with Epidermal Growth Factor Receptor Cancer Res., April 15, 2007; 67(8): 3609 - 3615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Broniscer, J. C. Panetta, M. O'Shaughnessy, C. Fraga, F. Bai, M. J. Krasin, A. Gajjar, and C. F. Stewart Plasma and Cerebrospinal Fluid Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420 Clin. Cancer Res., March 1, 2007; 13(5): 1511 - 1515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Failly, S. Korur, V. Egler, J.-L. Boulay, M. M. Lino, R. Imber, and A. Merlo Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells Mol. Cancer Ther., February 1, 2007; 6(2): 773 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. K. Mellinghoff, T. F. Cloughesy, and P. S. Mischel PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Clin. Cancer Res., January 15, 2007; 13(2): 378 - 381. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
